Parsortix test could avoid unnecessary prostate biopsies
Currently, investigation of symptoms for prostate cancer is typically made via an invasive blood test.
Read More
Tag: Angle
Angle’s ovarian cancer test could beat current standard
UK liquid biopsy group Angle has released trial findings that indicate its Parsortix blood test has the potential to out-perform the current standard of care in detecting ovarian cancer.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
